An accessible pharmacodynamic transcriptional biomarker for notch target engagement

Clinical Pharmacology and Therapeutics
Keith Q TanisRobert Iannone

Abstract

γ-Secretase mediates amyloid production in Alzheimer's disease (AD) and oncogenic activity of Notch. γ-Secretase inhibitors (GSIs) are thus of interest for AD and oncology. A peripheral biomarker of Notch activity would aid determination of the therapeutic window and dosing regimen for GSIs, given toxicities associated with chronic Notch inhibition. This study examined the effects of GSI MK-0752 on blood and hair follicle transcriptomes in healthy volunteers. The effects of a structurally diverse GSI on rhesus blood and hair follicles were also compared. Significant dose-related effects of MK-0752 on transcription were observed in hair follicles, but not blood. The GSI biomarker identified in follicles exhibited 100% accuracy in a clinical test cohort, and was regulated in rhesus by a structurally diverse GSI. This study identified a translatable, accessible pharmacodynamic biomarker of GSI target engagement and provides proof of concept of hair follicle RNA as a translatable biomarker source.

References

Mar 1, 1973·Archives of Otolaryngology·C M Monell, W E Berman
Nov 11, 1999·Oncogene·A DiévartP Jolicoeur
Dec 9, 2000·Developmental Biology·J S Mumm, R Kopan
Jul 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·P DoerflerR M Perlmutter
May 2, 2002·Cell·David AllmanWarren S Pear
Mar 13, 2003·Breast Cancer Research : BCR·Keith Brennan, Anthony M C Brown
Aug 4, 2004·Seminars in Cancer Biology·Katerina PolitiJan Kitajewski
Jun 28, 2005·Developmental Biology·Sophie VauclairFreddy Radtke
May 3, 2006·The Journal of Cell Biology·Mariko MoriyamaShin-Ichi Nishikawa
Jun 6, 2006·Proceedings of the National Academy of Sciences of the United States of America·Apostolos KlinakisArgiris Efstratiadis
Aug 22, 2006·Nature Reviews. Molecular Cell Biology·Sarah J Bray
Nov 23, 2006·Proceedings of the National Academy of Sciences of the United States of America·Teresa PalomeroAdolfo A Ferrando
Mar 18, 2008·Current Opinion in Cell Biology·Fiona M WattCarrie A Ambler
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Michael S Wolfe
Jan 24, 2009·Cellular and Molecular Life Sciences : CMLS·T Borggrefe, F Oswald
Feb 28, 2009·Blood·Kathleen CullionMichelle A Kelliher
Dec 4, 2010·European Journal of Cell Biology·Ralf SchwanbeckUrsula Just
Apr 22, 2011·Nature Reviews. Cancer·Prathibha RanganathanAnthony J Capobianco
Apr 23, 2011·Current Topics in Medicinal Chemistry·Bruno P Imbimbo, Giuseppe A M Giardina
Aug 2, 2011·Cancer Science·Shingo Miyamoto, Daniel W Rosenberg
May 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian KropPatricia Lorusso
Oct 1, 2013·Pharmacology & Therapeutics·Naoko TakebeSherry X Yang
Dec 10, 2013·Journal of Clinical Pharmacy and Therapeutics·J A MikulcaR B Raffa

❮ Previous
Next ❯

Citations

Jan 3, 2020·International Journal of Molecular Medicine·Masuko Katoh, Masaru Katoh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Transcription

Impaired transcription is associated with the pathogenesis and progression of conditions such as Alzheimer's disease (AD). Here are the latest discoveries pertaining to transcription and AD.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.